Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard sold 2,300 shares of Cumberland Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.24, for a total transaction of $12,052.00. Following the completion of the sale, the director now directly owns 32,131 shares of the company’s stock, valued at $168,366.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
CPIX stock traded down $0.07 during midday trading on Friday, hitting $5.07. The stock had a trading volume of 66,000 shares, compared to its average volume of 17,410. The firm has a market cap of $79.21 million, a PE ratio of -42.25 and a beta of 0.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.33 and a quick ratio of 1.85. Cumberland Pharmaceuticals, Inc. has a 12-month low of $4.70 and a 12-month high of $7.00. The company’s 50-day moving average price is $5.51 and its 200 day moving average price is $5.87.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. The firm had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $12.59 million. Cumberland Pharmaceuticals had a negative net margin of 9.87% and a positive return on equity of 5.04%. As a group, sell-side analysts anticipate that Cumberland Pharmaceuticals, Inc. will post 0.31 EPS for the current year.
Several analysts have commented on CPIX shares. Zacks Investment Research raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Wednesday, August 21st. ValuEngine cut shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Further Reading: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.